Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

The efficacy and safety of chidamide, a new subtype-selective histone deacetylase (HDAC) inhibitor, have been demonstrated in a pivotal phase II clinical trial, and chidamide has been approved by the China Food and Drug Administration (CFDA) as a treatment for relapsed or refractory peripheral T cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuankai, Jia, Bo, Xu, Wei, Li, Wenyu, Liu, Ting, Liu, Peng, Zhao, Weili, Zhang, Huilai, Sun, Xiuhua, Yang, Haiyan, Zhang, Xi, Jin, Jie, Jin, Zhengming, Li, Zhiming, Qiu, Lugui, Dong, Mei, Huang, Xiaobing, Luo, Yi, Wang, Xiaodong, Wang, Xin, Wu, Jianqiu, Xu, Jingyan, Yi, Pingyong, Zhou, Jianfeng, He, Hongming, Liu, Lin, Shen, Jianzhen, Tang, Xiaoqiong, Wang, Jinghua, Yang, Jianmin, Zeng, Qingshu, Zhang, Zhihui, Cai, Zhen, Chen, Xiequn, Ding, Kaiyang, Hou, Ming, Huang, Huiqiang, Li, Xiaoling, Liang, Rong, Liu, Qifa, Song, Yuqin, Su, Hang, Gao, Yuhuan, Liu, Lihong, Luo, Jianmin, Su, Liping, Sun, Zimin, Tan, Huo, Wang, Huaqing, Wang, Jingwen, Wang, Shuye, Zhang, Hongyu, Zhang, Xiaohong, Zhou, Daobin, Bai, Ou, Wu, Gang, Zhang, Liling, Zhang, Yizhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351273/
https://www.ncbi.nlm.nih.gov/pubmed/28298231
http://dx.doi.org/10.1186/s13045-017-0439-6

Ejemplares similares

Ejemplares similares